Alcon acquires Neurotech for USD 550 million. Needham keeps USD 98 target for Alcon stock

Published on 10/23/2026 at 09:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon acquired Neurotech for USD 550 million on October 20, 2026. Alcon stock costs EUR 62.38 on October 23, 2026.

Acquisition and analyst targets

Alcon acquired Neurotech Pharmaceuticals for USD 550 million on October 20, 2026.
Needham maintained a USD 98.00 price target on October 21, 2026.
Alcon stock trades at EUR 62.38 at 9:08 a.m. CEST at Lang & Schwarz on October 23, 2026.
Second-quarter 2026 revenue reached USD 2.78 billion.

Black and white photojournalism style. Ophthalmologist using slit-lamp biomicroscope to examine patient seated in optometry chair, strong chiaroscuro contrast, documentary grain, intimate clinical moment captured in wide horizontal frame — Alcon CH0432492467: Schwarz Weiß Fotografie eines Augenarztes mit Spaltlampe und Patient im Untersuchungsstuhl, Illustration mit AI erstellt.

Alcon (CH0432492467) was quoted at EUR 62.38 at Lang & Schwarz on October 23, 2026 at 9:08 a.m. CEST during pre-market trading. According to MarketBeat, Alcon acquired Neurotech Pharmaceuticals for USD 550 million on October 20, 2026, adding the ENCELTO retinal treatment to its portfolio.

Neurotech adds a retina asset

The transaction gives Alcon exposure to ENCELTO, which MarketBeat described as a treatment for adults with idiopathic macular telangiectasia type 2. The deal is the latest strategic move in a company that operates across Surgical and Vision Care, with products for eye surgeons, eye-care professionals and consumers.

Alcon's second-quarter 2026 adjusted earnings per share reached USD 0.84, above the USD 0.77 consensus estimate, while revenue rose 8.00 percent year over year to USD 2.78 billion, according to MarketBeat. The comparison gives investors a clearer benchmark for judging whether Neurotech can add to Alcon's existing growth profile.

What do the targets imply?

Needham analyst David Saxon reiterated a Buy rating and set a USD 98.00 target on October 21, 2026, according to Markets Insider. BTIG had cut its target to USD 74.00 from USD 82.00 on October 12, 2026, keeping a Buy rating, according to Markets Insider. The spread between those targets shows how differently analysts value the acquisition and Alcon's growth prospects.

Three recent dates and figures

On October 12, 2026, BTIG lowered its target from USD 82.00 to USD 74.00. On October 20, 2026, Alcon acquired Neurotech for USD 550 million. On October 21, 2026, Needham reiterated its Buy rating and set a USD 98.00 target.

Next reporting date

Alcon's next earnings release is scheduled for November 10, 2026, according to MarketScreener. That report will offer the next quantified test of operating progress after the acquisition.

Stock quote and company profile

Alcon stock was trading at EUR 62.38 at Lang & Schwarz on October 23, 2026 at 9:08 a.m. CEST. The primary listing is on the NYSE, where MarketBeat listed a market capitalization of USD 34.9 billion and a 52-week range of USD 61.83 to USD 87.64 as of October 22, 2026.

The further course of trading is shown by the continuously updated real-time quote of Alcon stock.